New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2014
08:50 EDTKPTIKaryopharm submits NADA for Verdinexor to FDA CVM
Karyopharm Therapeutics announced that it has submitted to the FDA Center for Veterinary Medicine, or CVM, the effectiveness and safety technical sections under a New Animal Drug Application, or NADA, for Verdinexor for the treatment of dogs with newly diagnosed or first relapsed non-Hodgkin lymphoma, or NHL. Verdinexor has received a designation from the CVM's Office of Minor Use and Minor Species, or MUMS, for the treatment of companion dogs with lymphoma, and the required portions of the NADA are being submitted initially under the CVM's MUMS guidelines.
News For KPTI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 10, 2014
10:04 EDTKPTIOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:27 EDTKPTIKaryopharm initiates clinical study of Selinexor
Subscribe for More Information
07:26 EDTKPTIKaryopharm sees existing cash, cash equivalents to fund R&D into 2H17
Karyopharm expects to end 2014 with greater than $200M in cash and cash equivalents.
07:26 EDTKPTIKaryopharm reports Q3 EPS (61c), consensus (52c)
Subscribe for More Information
07:18 EDTKPTIKaryopharm upgraded to Outperform from Perform at Oppenheimer
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use